You are here:

Forthcoming Submission: ribociclib (Kisqali)

Indication: for use in combination with an aromatase inhibitor (AI), for the treatment of postmenopausal women with HR+/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer as initial endocrine-based therapy.

Drug Details

Drug Name: ribociclib (Kisqali)
Drug Manufacturer: Novartis Pharmaceuticals UK Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
SMC Meeting Date: 6/02/2018
Advice Due: 12/03/2018